Prelude Therapeutics Inc Ordinary Shares PRLD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
-
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
-
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
Trading Information
- Previous Close Price
- $2.21
- Day Range
- $2.12–2.24
- 52-Week Range
- $1.66–6.80
- Bid/Ask
- $2.11 / $2.24
- Market Cap
- $116.65 Mil
- Volume/Avg
- 1 / 271,166
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 128
- Website
- https://www.preludetx.com
Comparables
Valuation
|
Metric
|
PRLD
|
CGON
|
ERAS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.64 | 4.57 | 1.62 |
Price/Sales | — | 252.33 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PRLD
CGON
ERAS
Financial Strength
|
Metric
|
PRLD
|
CGON
|
ERAS
|
|---|---|---|---|
Quick Ratio | 7.71 | 46.66 | 16.41 |
Current Ratio | 7.83 | 47.57 | 16.79 |
Interest Coverage | — | — | — |
Quick Ratio
PRLD
CGON
ERAS
Profitability
|
Metric
|
PRLD
|
CGON
|
ERAS
|
|---|---|---|---|
Return on Assets (Normalized) | −40.98% | −15.24% | −25.42% |
Return on Equity (Normalized) | −46.70% | −26.61% | −31.11% |
Return on Invested Capital (Normalized) | −44.57% | −25.60% | −31.15% |
Return on Assets
PRLD
CGON
ERAS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gyhwkgbz | Gsqvn | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fsynlplx | Jfjpjk | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lkkdrdph | Xhvrmb | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dfmjzltw | Wytqr | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Pphmkqgwx | Prtys | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Mkglxzlk | Ttzfs | $28.1 Bil | |||
| Moderna Inc
MRNA
| Wvyjjwvj | Pxyn | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Fnybvlvk | Nglt | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dtnrrsfh | Zlgwxry | $13.4 Bil | |||
| Incyte Corp
INCY
| Jyqgzhvp | Bbvgfzs | $12.7 Bil |
United States